Therapeutics

Cequa (ciclosporin 900 microgram/mL) is a newly-approved immunosuppressant indicated to increase tear production in affected patients where prior use of...

A new study has demonstrated that a particular biomarker can be used to select which age-related macular degeneration (AMD) patients...

Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the...